海正藥業(600267.SH):重慶恩創2371.5萬元成功摘牌海正宣泰51%股權
格隆匯12月26日丨海正藥業(600267.SH)公佈,截至2019年12月25日下午4:00,公司公開掛牌轉讓海正宣泰51%股權掛牌期滿。2019年12月26日,台交所確認重慶恩創醫療管理有限公司(“重慶恩創”)為成功摘牌方,摘牌價格為2371.5萬元人民幣,並且與公司完成《浙江海正宣泰醫藥有限公司51%股權轉讓合同》的簽署。
重慶恩創醫療管理有限公司經營範圍:醫療管理諮詢,健康管理諮詢,醫院管理諮詢,企業管理諮詢,市場信息諮詢,市場營銷策劃,從事醫療健康領域內的技術開發、技術諮詢、技術轉讓、技術服務,技術進出口等。
經公司財務測算,此次交易可確認歸屬於母公司所有者的淨利潤約為 2,091萬元。截至目前,相關工商變更登記手續尚未辦妥,因此此次交易實現的收益能否計入公司2019年度尚存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.